January 25, 2019 - 9:00am

Health and Human Services Commission, John H. Winters Human Services Complex, Public Hearing Room
701 West 51st St.
Austin, TX 78751

Add to My Calendar

 

Webcasting Available

  1. Call to order
  2. Approval of minutes from October 26, 2018 (vote required)
  3. New business

    Public comment on drug classes and therapeutic and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL):

    1. Acne agents, oral
    2. Acne agents, topical
    3. Analgesics, narcotic long
    4. Analgesics, narcotic short
    5. Angiotensin modulator combinations
    6. Angiotensin modulators
    7. Antimigraine agents, other
    8. Antimigraine agents, triptans
    9. Bladder relaxant preparations
    10. H. pylori treatment
    11. Immunomodulators, atopic dermatitis
    12. Intranasal rhinitis agents
    13. Movement disorders
    14. Neuropathic pain
    15. Phosphate binders
    16. Platelet aggregation inhibitors
    17. Progestins for cachexia
    18. Proton pump inhibitors
    19. Smoking cessation
    20. Stimulants and related agents
     

    Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:

    1. Ryclora / Antihistamines, first generation
    2. Vanalice Gel / Antiparasitics, topical
    3. Xofluza / Antivirals, oral
    4. Kapspargo / Beta-blockers
    5. Nivestym / Colony stimulating factors
    6. Ilumya Syringe / Cytokine and CAM antagonists
    7. Takhzyro / HAE treatments
    8. Panzyga / Immune globulins

  4. Therapeutic and clinical drug reviews and updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
  5. Executive work session

    Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

  6. Announcements of drugs recommended for the Medicaid PDL (vote required)
  7. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC
    1. Report on recent retrospective DUR interventions:
      1. Opioid prescribing
      2. Second generation antipsychotics in youth
    2. Report on recent retrospective DUR intervention outcomes:
      1. Attention deficit disorder/hyperactivity disorder (ADHD) high dose
      2. Psychotropic drugs in adults
      3. Migraine prevention and treatment
    3. Retrospective DUR proposals (vote required)
      1. Appropriate use of antibiotics
      2. Medication adherence
      3. Respiratory disease management
  8. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required )
    1. Cytokine and CAM antagonists - addition of Olumiant criteria
    2. Epidiolex - new criteria
    3. Orilissa - new criteria
  9. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. 5-HT3 receptor antagonists
    2. Angiotensin II receptor blockers
    3. Angiotensin-converting enzyme inhibitors
    4. ADHD medications
    5. GLP-1 receptor agonists
    6. Oral antidiabetic agents
    7. Pramlintide
    8. Serotonin 5-HT1B/1D receptor agonists
    9. Substance P / Neurokinin 1 receptor antagonists
  10. Adjourn
  11. Next meeting date: April 26, 2019

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6112 or Maribel.Castoreno@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings.

This meeting is open to the public. No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-707-6112 at least 72 hours before the meeting so appropriate arrangements can be made.